US · Healthcare · Biotechnology
EPS came in at -0.98 against a street estimate of -0.92 — a miss of 6.5%.
Analysts rate MoonLake Immunotherapeutics a strong buy (16 buy, 0 hold, 0 sell out of 16) with an average price target of $28.00.
| Fund | Stake |
|---|---|
| Bvf Inc | 18.81% |
| Deep Track Capital, LP | 7.53% |
| Cormorant Asset Management, LLC | 5.27% |
| HHG PLC | 4.06% |
| D. E. Shaw & Co LP | 2.81% |
| MPM Oncology Impact Management LP | 2.13% |
| Weiss Asset Management LP | 2.01% |
| Logos Global Management LP | 1.76% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-15 |
| Material agreement · Q2 2026 | 2026-06-25 |
| Reg FD disclosure · Q2 2026 | 2026-06-22 |
| Board / officer change · Q2 2026 | 2026-06-09 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Proxy statement · Q2 2026 | 2026-04-21 |
| Annual report FY2025 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for MoonLake Immunotherapeutics — free to start.
Google PlayApp StoreData updated 2026-08-05.